OICR-9429-N-C2-NH2 is primarily utilized in biomedical research, particularly in the study of epigenetic regulation and cancer therapeutics. It functions as a potent and selective inhibitor of protein-protein interactions, specifically targeting the WDR5-MLL complex, which plays a critical role in histone methylation and gene expression. By disrupting this interaction, it aids in understanding the mechanisms of leukemia and other cancers driven by MLL fusion proteins. Additionally, it serves as a valuable tool compound for developing novel epigenetic therapies and exploring the broader implications of chromatin remodeling in disease progression. Its application extends to drug discovery platforms, where it helps identify and validate new targets for cancer treatment.